FURUNO-ELECTRIC
20.8.2024 06:01:33 CEST | Business Wire | Press release
Furuno Electric is delighted to announce that the company will participate in Jammertest 2024 in Andøya, Norway from 9 to 13 September.
The participants will test GNSS receivers in an environment where they will actually be exposed to jamming and spoofing* signals and obtain data on their tolerance.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240819796325/en/
Jammertest 2024 (Graphic: Business Wire)
About Jammertest
This Jammertest is the world's largest test event where resistance to jamming and spoofing can be tested in a real environment. It is organized by the Norwegian Public Roads Administration, Norwegian Communications Authority, Norwegian Defence Research Establishment, Norwegian Metrology Service, Norwegian Space Agency and Testnor.
Jamming has actually been detected in the Black Sea, Northern Europe, and the Middle East, and there is a growing need for enhanced resiliency in critical infrastructure such as traffic control and mobile communications. Furuno has been testing its receivers by creating signals that simulate jamming and spoofing in a lab environment, but to verify and improve our anti-jamming capabilities, it is ideal to perform a variety of evaluations in a real environment. To allow participating companies and institutions to test their GNSS receiver-equipped products in a real-world environment, the organizer will conduct various types of jamming and spoofing attacks during the event.
The resistance test Furuno will carry out
In this Jammertest, Furuno will test the jamming and spoofing resistance of GT-100 which is Furuno’s timing multi-GNSS receiver module that supports dual-frequency band reception in the L1 and L5 bands. GNSS receivers for time synchronization are used in critical infrastructures that require robustness, such as 5G mobile base stations, TV broadcasting, financial institutions, and power grids. The latest product, GT-100, can automatically mitigate the effects of jamming and spoofing signals while providing users with real-time notification of the jamming signal frequency and signal strength. Also, if it completely loses reception of the L1 band signal, it can still maintain reception of the L5 band signal and continuously output stable time.
By participating in the Jammertest 2024, Furuno will evaluate and analyze the level of resistance of GT-100 to jamming and spoofing in real-world environments and use the results to further improve its robustness.
About Jammertest 2024
Official name of the event: Jammertest 2024
Event dates: September 9 - 13, 2024
Location: Andøya, Norway
Official website: https://jammertest.no/jammertest/
Products Tested
Timing Multi-GNSS Receiver Module GT-100
https://www.furuno.com/en/products/gnss-module/GT-100
Multi-GNSS Timing Antennas AU-500
https://www.furuno.com/en/products/gnss-antenna/AU-500
* Jamming and Spoofing: Jamming means radio waves that interfere with GNSS signals. Spoofing means that malicious actors intentionally mimic and broadcast GNSS-like signals with the intent to trick nearby GNSS receivers into calculating incorrect position and/or time.
Related Links
Announced on May 16, 2023: Furuno Announces High-Performance Multi-GNSS Timing Antennas
https://www.furuno.co.jp/en/news/general/general_category.html?itemid=1320&dispmid=961
Announced on September 14, 2022: Furuno Announces Most Advanced Global Timing Solutions Supporting L1 and L5 GNSS Signals
https://www.furuno.co.jp/en/news/general/general_category.html?itemid=1216&dispmid=961
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240819796325/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Yubico Appoints Poupak Modirassari Enbom as Chief Marketing Officer to Accelerate Global Momentum and Drive Market Leadership30.3.2026 15:00:00 CEST | Press release
Yubico (NASDAQ STOCKHOLM: YUBICO), the creator of the most secure passkeys and a leading provider of hardware authentication security keys, today announced the appointment of Poupak Enbom as Chief Marketing Officer (CMO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330278027/en/ Enbom joins Yubico at a pivotal moment as organizations worldwide accelerate the shift to phishing-resistant authentication and modern identity security in the age of AI. “We’re excited to welcome Poupak to Yubico,” said Jerrod Chong, acting chief executive officer, Yubico. “As the threat landscape evolves with AI-driven attacks and increasing automation, organizations are rethinking how they secure digital identities of both humans and AI agents at scale. She brings a unique combination of technical depth, global leadership, and customer-first mindset that will help us continue to expand our impact and support our customers and partners around
Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 14:00:00 CEST | Press release
Fuel manufactured at Springfields has generated enough energy to supply the UK’s electricity demand for 26 years, avoiding the emission of nearly 3 billion tonnes of CO2 The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 5
HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 14:00:00 CEST | Press release
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom